linghui personal page - To The Moon

linghui

No personal profile

3Follow

0Followers

0Topic

0Badge

2022-02-14

Great ariticle, would you like to share it?

@OptionPlus:Option Recap: Don't take chestnuts out of the fire

2022-02-10

sigh

@BaronLyly:$Marathon Digital Holdings Inc(MARA)$ you won’t see much growth here . You should be banking on FRTTF$FORTRESS TECHNOLOGIES INC.(FRTTF)$ and LUXXF$LUXXFOLIO HLDGS INC(LUXFF)$ as they will double , triple and very cheap . I bought MARA and RIOT$Riot Blockchain, Inc.(RIOT)$ as a penny stock last year so jump on same. Easier to double and triple your money if you buy low hanging fruit .looks like accumulation before the next leg up

2022-02-05

Ok

Apple Aims to Debut a New Low-Cost 5G iPhone and iPad in Early March

2022-02-05

Ok

Metauniverse Stocks Slid in Premarket Trading,With Block and Roblox Falling Over 6%

2022-02-03

Ok

10 Biggest Price Target Changes For Wednesday

2022-02-03

Thanks

2 Biotech Stocks That Could Make You Richer

2022-02-02

Ok

AT&T Is Getting Closer to a Clean Slate. Here’s What Comes Next

2022-02-02

Ok

Sorry, the original content has been removed

2022-02-02

Gd info

MicroStrategy shares rose 7% in premarket trading

2022-02-02

Above ok!

Sorry, the original content has been removed

2022-02-02

Ok

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582933493509774","uuid":"3582933493509774","gmtCreate":1619839469204,"gmtModify":1706397937718,"name":"linghui","pinyin":"linghui","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9095302361,"gmtCreate":1644813840775,"gmtModify":1676533964421,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095302361","repostId":"9092755406","repostType":1,"repost":{"id":9092755406,"gmtCreate":1644742715482,"gmtModify":1676533958368,"author":{"id":"3527667591235607","authorId":"3527667591235607","name":"OptionPlus","avatar":"https://static.tigerbbs.com/e8009c23927adcf8b5e1e1d101178392","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667591235607","idStr":"3527667591235607"},"themes":[],"title":"Option Recap: Don't take chestnuts out of the fire","htmlText":"The general idea is similar to last week, so I dont do detailed review，you can read&nbsp;my&nbsp;review&nbsp;for&nbsp;last&nbsp;week&nbsp;if&nbsp;you&nbsp;like. The&nbsp;S&amp;P&nbsp;500&nbsp;fell&nbsp;be&nbsp;its&nbsp;anual&nbsp;support&nbsp;line&nbsp;again&nbsp;in&nbsp;the&nbsp;second&nbsp;half&nbsp;of&nbsp;Friday&nbsp;night&nbsp;with&nbsp;geopolitical shocks.&nbsp;And&nbsp;It&nbsp;closed&nbsp;at&nbsp;a&nbsp;weely&nbsp;low&nbsp;point.&nbsp;My&nbsp;feeling&nbsp;is&nbsp;similar&nbsp;to&nbsp;last&nbsp;week,&nbsp;it&nbsp;might&nbsp;draw&nbsp;a&nbsp;right-leg. There&nbsp;is&nbsp;a&nbsp;small&nbsp;double-top&nbsp;in&nbsp;past&nbsp;two&nbsp;weeks,&nbsp;and&nbsp;both&nbsp;small&nbsp;tops&nbsp;did&nbsp;not&nbsp;rally&nbsp;to&nbsp;the&nbsp;MA50,&nbsp;it&nbsp;was&nbsp;not&nbsp;strong.&nbsp;As&nbsp;","listText":"The general idea is similar to last week, so I dont do detailed review，you can read&nbsp;my&nbsp;review&nbsp;for&nbsp;last&nbsp;week&nbsp;if&nbsp;you&nbsp;like. The&nbsp;S&amp;P&nbsp;500&nbsp;fell&nbsp;be&nbsp;its&nbsp;anual&nbsp;support&nbsp;line&nbsp;again&nbsp;in&nbsp;the&nbsp;second&nbsp;half&nbsp;of&nbsp;Friday&nbsp;night&nbsp;with&nbsp;geopolitical shocks.&nbsp;And&nbsp;It&nbsp;closed&nbsp;at&nbsp;a&nbsp;weely&nbsp;low&nbsp;point.&nbsp;My&nbsp;feeling&nbsp;is&nbsp;similar&nbsp;to&nbsp;last&nbsp;week,&nbsp;it&nbsp;might&nbsp;draw&nbsp;a&nbsp;right-leg. There&nbsp;is&nbsp;a&nbsp;small&nbsp;double-top&nbsp;in&nbsp;past&nbsp;two&nbsp;weeks,&nbsp;and&nbsp;both&nbsp;small&nbsp;tops&nbsp;did&nbsp;not&nbsp;rally&nbsp;to&nbsp;the&nbsp;MA50,&nbsp;it&nbsp;was&nbsp;not&nbsp;strong.&nbsp;As&nbsp;","text":"The general idea is similar to last week, so I dont do detailed review，you can read my review for last week if you like. The S&P 500 fell be its anual support line again in the second half of Friday night with geopolitical shocks. And It closed at a weely low point. My feeling is similar to last week, it might draw a right-leg. There is a small double-top in past two weeks, and both small tops did not rally to the MA50, it was not strong. As","images":[{"img":"https://static.tigerbbs.com/ed0379ee21b4ee0665a09e0210e754a4","width":"2096","height":"1220"},{"img":"https://static.tigerbbs.com/cbe5974fdf018ff5b17c62544ec1de99","width":"2144","height":"1534"},{"img":"https://static.tigerbbs.com/cc0af868946c5e3165b2c5dad80913e6","width":"2198","height":"1332"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092755406","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9092993723,"gmtCreate":1644504373762,"gmtModify":1676533934446,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"sigh","listText":"sigh","text":"sigh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092993723","repostId":"696619638","repostType":1,"repost":{"id":696619638,"gmtCreate":1640679651873,"gmtModify":1676532477490,"author":{"id":"9000000000000695","authorId":"9000000000000695","name":"BaronLyly","avatar":"https://static.tigerbbs.com/2002537f0b7be973a9a9a72fea618459","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000695","idStr":"9000000000000695"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MARA\">$Marathon Digital Holdings Inc(MARA)$</a> you won’t see much growth here . You should be banking on FRTTF<a href=\"https://laohu8.com/S/FRTTF\">$FORTRESS TECHNOLOGIES INC.(FRTTF)$</a> and LUXXF<a href=\"https://laohu8.com/S/LUXFF\">$LUXXFOLIO HLDGS INC(LUXFF)$</a> as they will double , triple and very cheap . I bought MARA and RIOT<a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$</a> as a penny stock last year so jump on same. Easier to double and triple your money if you buy low hanging fruit .looks like accumulation before the next leg up","listText":"<a href=\"https://laohu8.com/S/MARA\">$Marathon Digital Holdings Inc(MARA)$</a> you won’t see much growth here . You should be banking on FRTTF<a href=\"https://laohu8.com/S/FRTTF\">$FORTRESS TECHNOLOGIES INC.(FRTTF)$</a> and LUXXF<a href=\"https://laohu8.com/S/LUXFF\">$LUXXFOLIO HLDGS INC(LUXFF)$</a> as they will double , triple and very cheap . I bought MARA and RIOT<a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$</a> as a penny stock last year so jump on same. Easier to double and triple your money if you buy low hanging fruit .looks like accumulation before the next leg up","text":"$Marathon Digital Holdings Inc(MARA)$ you won’t see much growth here . You should be banking on FRTTF$FORTRESS TECHNOLOGIES INC.(FRTTF)$ and LUXXF$LUXXFOLIO HLDGS INC(LUXFF)$ as they will double , triple and very cheap . I bought MARA and RIOT$Riot Blockchain, Inc.(RIOT)$ as a penny stock last year so jump on same. Easier to double and triple your money if you buy low hanging fruit .looks like accumulation before the next leg up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/696619638","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098309708,"gmtCreate":1644020507382,"gmtModify":1676533881869,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098309708","repostId":"2209345239","repostType":4,"repost":{"id":"2209345239","kind":"news","pubTimestamp":1644016922,"share":"https://ttm.financial/m/news/2209345239?lang=en_US&edition=fundamental","pubTime":"2022-02-05 07:22","market":"us","language":"en","title":"Apple Aims to Debut a New Low-Cost 5G iPhone and iPad in Early March","url":"https://stock-news.laohu8.com/highlight/detail?id=2209345239","media":"Bloomberg","summary":"Apple Inc. is targeting a date on or near March 8 to unveil a new low-cost iPhone and an updated iPad, according to people with knowledge of the matter, kicking off a potentially record-setting year f","content":"<div>\n<p>Apple Inc. is targeting a date on or near March 8 to unveil a new low-cost iPhone and an updated iPad, according to people with knowledge of the matter, kicking off a potentially record-setting year ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apple-aims-debut-low-cost-193822024.html\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Aims to Debut a New Low-Cost 5G iPhone and iPad in Early March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Aims to Debut a New Low-Cost 5G iPhone and iPad in Early March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/apple-aims-debut-low-cost-193822024.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple Inc. is targeting a date on or near March 8 to unveil a new low-cost iPhone and an updated iPad, according to people with knowledge of the matter, kicking off a potentially record-setting year ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apple-aims-debut-low-cost-193822024.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4017":"黄金","BK4534":"瑞士信贷持仓","BK4515":"5G概念","BK4559":"巴菲特持仓","AAPL":"苹果","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4527":"明星科技股","BK4554":"元宇宙及AR概念","BK4501":"段永平概念","BK4507":"流媒体概念","BK4566":"资本集团","BK4553":"喜马拉雅资本持仓","NGD":"New Gold","BK4550":"红杉资本持仓","BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边"},"source_url":"https://finance.yahoo.com/news/apple-aims-debut-low-cost-193822024.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2209345239","content_text":"Apple Inc. is targeting a date on or near March 8 to unveil a new low-cost iPhone and an updated iPad, according to people with knowledge of the matter, kicking off a potentially record-setting year for product launches.The announcement will mark Apple’s first major event since a new MacBook Pro debuted in October. Like the company’s other recent launches, it’s expected to be an online presentation rather than in-person, said the people, who asked not to be identified because the deliberations are private.Apple is coming off a holiday quarter that far exceeded Wall Street predictions, helping quell fears that supply-chain problems would hurt sales. Now the company is setting its sights higher for 2022. The March announcements -- along with the usual flood of product news expected later in 2022 -- suggest Apple will introduce its biggest crop of new devices ever in a single year.Given that the planned timing is still more than a month away, the company’s plans may change in the face of production delays or other changes, the people said. An Apple spokeswoman declined to comment on the company’s plans.The new phone will be the first update to the iPhone SE model in two years, adding 5G network capabilities, an improved camera and a faster processor. But the design itself is expected to be similar to the current version, which debuted in April 2020.The new iPad, meanwhile, will be an update to the Air model that features a faster processor and 5G. The company is also planning a new Mac with Apple-designed chips, which could also come as early as March.In addition to announcing new devices, the company is planning to release iOS 15.4 in the first half of March, the people said. The software update will add Face ID support for people wearing masks to iPhones and iPads, making it easier for users to unlock their devices. It also has new emojis and Universal Control, which lets customers use a single keyboard and trackpad across multiple iPads and Macs.Following the March event, the company will likely hold its annual Worldwide Developers Conference in June to announce software updates for the iPhone, iPad, Mac and Apple Watch. It’s then expected to hold multiple keynote events in the fall to launch the iPhone 14 and new Macs.The 2022 lineup is likely to include new iMac and Mac Pro desktops, a redesigned MacBook Air, an updated low-end MacBook Pro, three Apple Watches, four iPhone 14 models and new AirPods. The company is also planning new services, such as a feature that lets the iPhone accept payments with the tap of a credit card.Apple is working on a high-end mixed reality headset as well, but that’s now more likely to be released in 2023. The company had aimed to announce the device as early as the end of 2022, but development challenges have delayed the timing, Bloomberg reported last month.","news_type":1,"symbols_score_info":{"NGD":1,"AAPL":1}},"isVote":1,"tweetType":1,"viewCount":2334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098309592,"gmtCreate":1644020478679,"gmtModify":1676533881861,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098309592","repostId":"1133568920","repostType":4,"repost":{"id":"1133568920","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643879102,"share":"https://ttm.financial/m/news/1133568920?lang=en_US&edition=fundamental","pubTime":"2022-02-03 17:05","market":"us","language":"en","title":"Metauniverse Stocks Slid in Premarket Trading,With Block and Roblox Falling Over 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133568920","media":"Tiger Newspress","summary":"Metauniverse stocks slid in premarket trading, with Block and Roblox falling over6%.In Meta’s financ","content":"<html><head></head><body><p>Metauniverse stocks slid in premarket trading, with Block and Roblox falling over6%.</p><p><img src=\"https://static.tigerbbs.com/9bf35520675a25a430afdadb73298193\" tg-width=\"287\" tg-height=\"191\" referrerpolicy=\"no-referrer\"/></p><p>In Meta’s financial result ,it disclosed the data of FRL department including metauniverse strategy for the first time. The company expected that the investment in metauniverse will reduce the operating profit by about US $10 billion in 2021, and FRL will not make a profit in the short term.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Metauniverse Stocks Slid in Premarket Trading,With Block and Roblox Falling Over 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetauniverse Stocks Slid in Premarket Trading,With Block and Roblox Falling Over 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-03 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Metauniverse stocks slid in premarket trading, with Block and Roblox falling over6%.</p><p><img src=\"https://static.tigerbbs.com/9bf35520675a25a430afdadb73298193\" tg-width=\"287\" tg-height=\"191\" referrerpolicy=\"no-referrer\"/></p><p>In Meta’s financial result ,it disclosed the data of FRL department including metauniverse strategy for the first time. The company expected that the investment in metauniverse will reduce the operating profit by about US $10 billion in 2021, and FRL will not make a profit in the short term.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133568920","content_text":"Metauniverse stocks slid in premarket trading, with Block and Roblox falling over6%.In Meta’s financial result ,it disclosed the data of FRL department including metauniverse strategy for the first time. The company expected that the investment in metauniverse will reduce the operating profit by about US $10 billion in 2021, and FRL will not make a profit in the short term.","news_type":1,"symbols_score_info":{"SQ":0.9,"RBLX":0.9}},"isVote":1,"tweetType":1,"viewCount":2250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091661999,"gmtCreate":1643853421813,"gmtModify":1676533863822,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091661999","repostId":"1178657302","repostType":4,"repost":{"id":"1178657302","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1643804908,"share":"https://ttm.financial/m/news/1178657302?lang=en_US&edition=fundamental","pubTime":"2022-02-02 20:28","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1178657302","media":"Benzinga","summary":"Keybanc lifted the price target for Alphabet Inc. from $3,090 to $3,400. Alphabet shares surged 11% ","content":"<html><head></head><body><ul><li>Keybanc lifted the price target for <b>Alphabet Inc.</b> from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading.</li><li>Wedbush cut the price target on <b>Starbucks Corporation</b> from $110 to $106. Starbucks shares fell 2.5% to $96.29 in pre-market trading.</li><li>Cowen &amp; Co. cut <b>Clover Health Investments, Corp.</b> price target from $7 to $3. Clover Health Investments shares rose 6.5% to $2.97 in pre-market trading.</li><li>UBS lowered <b>Zimmer Biomet Holdings, Inc.</b> price target from $172 to $130. Zimmer Biomet shares fell 0.2% to $123.80 in pre-market trading.</li><li>Citigroup cut <b>loanDepot, Inc.</b> price target from $12 to $5. loanDepot shares fell 4.9% to close at $4.46 on Tuesday.</li></ul><ul><li>Raymond James boosted the price target for <b>NXP Semiconductors N.V.</b> from $250 to $260. NXP Semiconductors shares rose 1.4% to $211.10 in pre-market trading.</li><li>SVB Leerink raised the price target on <b>Bio-Techne Corporation</b> from $530 to $575. Bio-Techne shares rose 0.1% to $401.76 in pre-market trading.</li><li>Goldman Sachs lowered <b>2U, Inc.</b> price target from $42 to $25. 2U shares rose 6.7% to $17.79 in pre-market trading.</li><li>UBS cut the price target on <b>Etsy, Inc.</b> from $215 to $180. Etsy shares rose 2% to $155.16 in pre-market trading.</li><li>Keybanc cut <b>PayPal Holdings, Inc.</b> price target from $250 to $200. PayPal shares fell 16% to $148.00 in pre-market trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-02-02 20:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><ul><li>Keybanc lifted the price target for <b>Alphabet Inc.</b> from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading.</li><li>Wedbush cut the price target on <b>Starbucks Corporation</b> from $110 to $106. Starbucks shares fell 2.5% to $96.29 in pre-market trading.</li><li>Cowen &amp; Co. cut <b>Clover Health Investments, Corp.</b> price target from $7 to $3. Clover Health Investments shares rose 6.5% to $2.97 in pre-market trading.</li><li>UBS lowered <b>Zimmer Biomet Holdings, Inc.</b> price target from $172 to $130. Zimmer Biomet shares fell 0.2% to $123.80 in pre-market trading.</li><li>Citigroup cut <b>loanDepot, Inc.</b> price target from $12 to $5. loanDepot shares fell 4.9% to close at $4.46 on Tuesday.</li></ul><ul><li>Raymond James boosted the price target for <b>NXP Semiconductors N.V.</b> from $250 to $260. NXP Semiconductors shares rose 1.4% to $211.10 in pre-market trading.</li><li>SVB Leerink raised the price target on <b>Bio-Techne Corporation</b> from $530 to $575. Bio-Techne shares rose 0.1% to $401.76 in pre-market trading.</li><li>Goldman Sachs lowered <b>2U, Inc.</b> price target from $42 to $25. 2U shares rose 6.7% to $17.79 in pre-market trading.</li><li>UBS cut the price target on <b>Etsy, Inc.</b> from $215 to $180. Etsy shares rose 2% to $155.16 in pre-market trading.</li><li>Keybanc cut <b>PayPal Holdings, Inc.</b> price target from $250 to $200. PayPal shares fell 16% to $148.00 in pre-market trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp","GOOGL":"谷歌A","ZBH":"齐默巴奥米特控股","PYPL":"PayPal","TECH":"Techne Corporation","ETSY":"Etsy, Inc.","SBUX":"星巴克","NXPI":"恩智浦","TWOU":"2U Inc","LDI":"loanDepot, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178657302","content_text":"Keybanc lifted the price target for Alphabet Inc. from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading.Wedbush cut the price target on Starbucks Corporation from $110 to $106. Starbucks shares fell 2.5% to $96.29 in pre-market trading.Cowen & Co. cut Clover Health Investments, Corp. price target from $7 to $3. Clover Health Investments shares rose 6.5% to $2.97 in pre-market trading.UBS lowered Zimmer Biomet Holdings, Inc. price target from $172 to $130. Zimmer Biomet shares fell 0.2% to $123.80 in pre-market trading.Citigroup cut loanDepot, Inc. price target from $12 to $5. loanDepot shares fell 4.9% to close at $4.46 on Tuesday.Raymond James boosted the price target for NXP Semiconductors N.V. from $250 to $260. NXP Semiconductors shares rose 1.4% to $211.10 in pre-market trading.SVB Leerink raised the price target on Bio-Techne Corporation from $530 to $575. Bio-Techne shares rose 0.1% to $401.76 in pre-market trading.Goldman Sachs lowered 2U, Inc. price target from $42 to $25. 2U shares rose 6.7% to $17.79 in pre-market trading.UBS cut the price target on Etsy, Inc. from $215 to $180. Etsy shares rose 2% to $155.16 in pre-market trading.Keybanc cut PayPal Holdings, Inc. price target from $250 to $200. PayPal shares fell 16% to $148.00 in pre-market trading.","news_type":1,"symbols_score_info":{"CLOV":0.9,"TECH":0.9,"TWOU":0.9,"SBUX":0.9,"ZBH":0.9,"LDI":0.9,"PYPL":0.9,"GOOGL":0.9,"NXPI":0.9,"ETSY":0.9}},"isVote":1,"tweetType":1,"viewCount":1798,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091660170,"gmtCreate":1643852941827,"gmtModify":1676533863751,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091660170","repostId":"1196109622","repostType":4,"repost":{"id":"1196109622","kind":"news","pubTimestamp":1643852105,"share":"https://ttm.financial/m/news/1196109622?lang=en_US&edition=fundamental","pubTime":"2022-02-03 09:35","market":"us","language":"en","title":"2 Biotech Stocks That Could Make You Richer","url":"https://stock-news.laohu8.com/highlight/detail?id=1196109622","media":"Motley Fool","summary":"Investing in the stock market won't make you rich overnight. But with a patient approach to investin","content":"<html><head></head><body><p>Investing in the stock market won&#39;t make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.</p><p>Let&#39;s address the second part of this strategy: picking the right stocks, which isn&#39;t always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a> and <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a>. Here&#39;s why.</p><p>1. <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a></p><p>To say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.</p><p>On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.</p><p>However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called<b>2Seventy Bio</b>.</p><p>Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.</p><p>There are few treatments for TDT. But Bluebird&#39;s version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.</p><p>The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).</p><p>ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.</p><p>Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.</p><p>However, Bluebird&#39;s current market cap is barely over $500 million. The market isn&#39;t putting much value in the company&#39;s programs at all. That&#39;s what makes this biotech a potentially attractive option. If the company&#39;s master plan actualizes, its shares could skyrocket.</p><p>2. <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a></p><p>Exelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company&#39;s sales. But thebiotech&#39;s reliance on its crown jewel doesn&#39;t bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.</p><p>Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.</p><p>First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it&#39;s estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it&#39;s predicting $1.3 billion to $1.4 billion in revenue.</p><p>Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That&#39;s good news for Exelixis and its shareholders.</p><p>The biotech is now looking to replicate the success it&#39;s had with Cabometyx. It&#39;s advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.</p><p>Within the next couple of years, these products should be moving into late-stage studies. Exelixis&#39; forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotech Stocks That Could Make You Richer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotech Stocks That Could Make You Richer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯"},"source_url":"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196109622","content_text":"Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: Bluebird Bio and Exelixis. Here's why.1. Bluebird BioTo say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called2Seventy Bio.Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.2. ExelixisExelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.","news_type":1,"symbols_score_info":{"EXEL":0.9,"BLUE":0.9}},"isVote":1,"tweetType":1,"viewCount":2007,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091972266,"gmtCreate":1643768850684,"gmtModify":1676533853939,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091972266","repostId":"1100073306","repostType":4,"repost":{"id":"1100073306","kind":"news","pubTimestamp":1643762185,"share":"https://ttm.financial/m/news/1100073306?lang=en_US&edition=fundamental","pubTime":"2022-02-02 08:36","market":"us","language":"en","title":"AT&T Is Getting Closer to a Clean Slate. Here’s What Comes Next","url":"https://stock-news.laohu8.com/highlight/detail?id=1100073306","media":"Barron's","summary":"After a saga of misguided M&A, there’s still work to be done for AT&T. Patrick T. Fallon/AFP via Get","content":"<html><head></head><body><p>After a saga of misguided M&amp;A, there’s still work to be done for AT&amp;T. Patrick T. Fallon/AFP via Getty Images</p><p>AT&amp;T shed some light on its pending exit from the media business on Tuesday, elaborating on the mechanics of this year’s mega-transaction to spin off WarnerMedia and merge it with Discovery. It’s one more step toward putting a saga of misguided M&amp;A behind it, but there’s still work to be done.</p><p>AT&amp;T (ticker: T) spent much of the past decade bulking up and dishing out billions of dollars on several acquisitions. The biggest were a $66 billion deal for DirecTV, which closed in July 2015, and the $106 billion acquisition of Time Warner, which closed in June 2018. That brought the 145-year-old phone business into new and more cyclical industries, and at one point made it the most-indebted company in the U.S.</p><p>Since the start of 2021 and under a new CEO, John Stankey, AT&amp;T has been slimming down. A spinoff of DirecTV and the company’s other pay-TV operations was announced and completed last year. Its Xandr advertising platform is being sold to Microsoft ( MSFT ). And the spinoff of WarnerMedia should close in the second quarter of this year, per management.</p><p>It will leave AT&amp;T with a telecom-only portfolio of businesses focused on 5G wireless and fiber-optic broadband. Those are high fixed-cost businesses, but also bring attractive economies of scale and recurring revenue from subscribers.</p><p>Shedding its conglomerate structure won’t make the challenges AT&amp;T faces in its telecom businesses go away, but it will allow management to focus time and resources on solving them. Competitive dynamics in both wired and wireless communications appear to be getting more intense, especially as industry subscriber growth slows following a pandemic-era boost. And AT&amp;T requires tens of billions of dollars in capital expenditures to improve its 5G and fiber networks.</p><p>AT&amp;T plans to expand its 5G C-band network to 200 million people in the U.S. by the end of 2023, and wants to reach 30 million homes and businesses with its fiber network by the end of 2025.</p><p>AT&amp;T will have more financial firepower to throw at those goals. Management expects $20 billion of annual free cash flow from the post-WarnerMedia telecom company, with 40% of that, or $8 billion, going toward its dividend. That compares with a $15 billion annual dividend commitment prior to the spinoff. The new payout will be some $1.11 per share annually, or a 6.3% yield at current prices (adjusting for the roughly $6.70 a share in Warner Bros. Discovery stock that AT&amp;T holders will receive). It matches the projections that AT&amp;T gave when announcing the transaction in May 2021.</p><p>AT&amp;T management expects to spend around $24 billion on capital investments in 2022. And the company will get an estimated $43 billion via the WarnerMedia transaction to put toward paying down debt. Management expects to get net debt to adjusted earnings before interest, taxes, depreciation, and amortization—or Ebitda—down to 2.5 times by the end of 2023. That compares with about 3.2 times today.</p><p>The result should be a leaner, meaner AT&amp;T that’s better equipped to face its challenges, but investors will want to see proof after feeling burned by years of management decisions that look poor in hindsight. Next up is a virtual investor day on March 11 focused on the post-WarnerMedia telecom business, which could include new long-term targets and plans.</p><p>The closing of the transaction itself should also bring some relief. Investors interested in Warner Bros. Discovery can shift to that stock, and those who want a yield-generating telecom stock can double down on AT&amp;T. Most of all, it will allow Wall Street to focus on AT&amp;T’s fundamentals and judge management on operations—and put an end to years of distracting and expensive M&amp;A sagas.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AT&T Is Getting Closer to a Clean Slate. Here’s What Comes Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAT&T Is Getting Closer to a Clean Slate. Here’s What Comes Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-02 08:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/att-media-spin-51643742609?mod=hp_LEAD_1><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a saga of misguided M&A, there’s still work to be done for AT&T. Patrick T. Fallon/AFP via Getty ImagesAT&T shed some light on its pending exit from the media business on Tuesday, elaborating on...</p>\n\n<a href=\"https://www.barrons.com/articles/att-media-spin-51643742609?mod=hp_LEAD_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"T":"At&T"},"source_url":"https://www.barrons.com/articles/att-media-spin-51643742609?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100073306","content_text":"After a saga of misguided M&A, there’s still work to be done for AT&T. Patrick T. Fallon/AFP via Getty ImagesAT&T shed some light on its pending exit from the media business on Tuesday, elaborating on the mechanics of this year’s mega-transaction to spin off WarnerMedia and merge it with Discovery. It’s one more step toward putting a saga of misguided M&A behind it, but there’s still work to be done.AT&T (ticker: T) spent much of the past decade bulking up and dishing out billions of dollars on several acquisitions. The biggest were a $66 billion deal for DirecTV, which closed in July 2015, and the $106 billion acquisition of Time Warner, which closed in June 2018. That brought the 145-year-old phone business into new and more cyclical industries, and at one point made it the most-indebted company in the U.S.Since the start of 2021 and under a new CEO, John Stankey, AT&T has been slimming down. A spinoff of DirecTV and the company’s other pay-TV operations was announced and completed last year. Its Xandr advertising platform is being sold to Microsoft ( MSFT ). And the spinoff of WarnerMedia should close in the second quarter of this year, per management.It will leave AT&T with a telecom-only portfolio of businesses focused on 5G wireless and fiber-optic broadband. Those are high fixed-cost businesses, but also bring attractive economies of scale and recurring revenue from subscribers.Shedding its conglomerate structure won’t make the challenges AT&T faces in its telecom businesses go away, but it will allow management to focus time and resources on solving them. Competitive dynamics in both wired and wireless communications appear to be getting more intense, especially as industry subscriber growth slows following a pandemic-era boost. And AT&T requires tens of billions of dollars in capital expenditures to improve its 5G and fiber networks.AT&T plans to expand its 5G C-band network to 200 million people in the U.S. by the end of 2023, and wants to reach 30 million homes and businesses with its fiber network by the end of 2025.AT&T will have more financial firepower to throw at those goals. Management expects $20 billion of annual free cash flow from the post-WarnerMedia telecom company, with 40% of that, or $8 billion, going toward its dividend. That compares with a $15 billion annual dividend commitment prior to the spinoff. The new payout will be some $1.11 per share annually, or a 6.3% yield at current prices (adjusting for the roughly $6.70 a share in Warner Bros. Discovery stock that AT&T holders will receive). It matches the projections that AT&T gave when announcing the transaction in May 2021.AT&T management expects to spend around $24 billion on capital investments in 2022. And the company will get an estimated $43 billion via the WarnerMedia transaction to put toward paying down debt. Management expects to get net debt to adjusted earnings before interest, taxes, depreciation, and amortization—or Ebitda—down to 2.5 times by the end of 2023. That compares with about 3.2 times today.The result should be a leaner, meaner AT&T that’s better equipped to face its challenges, but investors will want to see proof after feeling burned by years of management decisions that look poor in hindsight. Next up is a virtual investor day on March 11 focused on the post-WarnerMedia telecom business, which could include new long-term targets and plans.The closing of the transaction itself should also bring some relief. Investors interested in Warner Bros. Discovery can shift to that stock, and those who want a yield-generating telecom stock can double down on AT&T. Most of all, it will allow Wall Street to focus on AT&T’s fundamentals and judge management on operations—and put an end to years of distracting and expensive M&A sagas.","news_type":1,"symbols_score_info":{"T":0.9}},"isVote":1,"tweetType":1,"viewCount":2524,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091972866,"gmtCreate":1643768833295,"gmtModify":1676533853931,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091972866","repostId":"2208351417","repostType":4,"isVote":1,"tweetType":1,"viewCount":2098,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091976377,"gmtCreate":1643768778805,"gmtModify":1676533853907,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Gd info","listText":"Gd info","text":"Gd info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091976377","repostId":"1181481003","repostType":4,"repost":{"id":"1181481003","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643722728,"share":"https://ttm.financial/m/news/1181481003?lang=en_US&edition=fundamental","pubTime":"2022-02-01 21:38","market":"us","language":"en","title":"MicroStrategy shares rose 7% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1181481003","media":"Tiger Newspress","summary":"MicroStrategy shares rose 7% in premarket trading.As of Jan. 31, the company held about 125,051 bitc","content":"<html><head></head><body><p>MicroStrategy shares rose 7% in premarket trading.<img src=\"https://static.tigerbbs.com/9682bd3ba54feb42c63bc9be06e419fa\" tg-width=\"699\" tg-height=\"598\" width=\"100%\" height=\"auto\"/></p><p>As of Jan. 31, the company held about 125,051 bitcoins purchased at an average price of $30,200.</p><p>MicroStrategy (Nasdaq: MSTR), the business-intelligence software company that’s taken to accumulating bitcoin, said it bought approximately 660 bitcoins for around $25 million between Dec. 30, 2021 and Jan. 31, 2022.</p><p>The company paid an average price of $37,865 per bitcoin, it said in a statement.</p><p>Tysons Corner, Virginia-based MicroStrategy now holds a total of 125,051 bitcoins, valued at about $4.8 billion at the current bitcoin price of $38,700.</p><p>Shares of MicroStrategy have fallen around 34% over the last month.</p><p>CEO Michael Saylor has been insistent that the company has no plans to sell its bitcoin holdings and is in for the long-term.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MicroStrategy shares rose 7% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicroStrategy shares rose 7% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-01 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>MicroStrategy shares rose 7% in premarket trading.<img src=\"https://static.tigerbbs.com/9682bd3ba54feb42c63bc9be06e419fa\" tg-width=\"699\" tg-height=\"598\" width=\"100%\" height=\"auto\"/></p><p>As of Jan. 31, the company held about 125,051 bitcoins purchased at an average price of $30,200.</p><p>MicroStrategy (Nasdaq: MSTR), the business-intelligence software company that’s taken to accumulating bitcoin, said it bought approximately 660 bitcoins for around $25 million between Dec. 30, 2021 and Jan. 31, 2022.</p><p>The company paid an average price of $37,865 per bitcoin, it said in a statement.</p><p>Tysons Corner, Virginia-based MicroStrategy now holds a total of 125,051 bitcoins, valued at about $4.8 billion at the current bitcoin price of $38,700.</p><p>Shares of MicroStrategy have fallen around 34% over the last month.</p><p>CEO Michael Saylor has been insistent that the company has no plans to sell its bitcoin holdings and is in for the long-term.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSTR":"Strategy"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181481003","content_text":"MicroStrategy shares rose 7% in premarket trading.As of Jan. 31, the company held about 125,051 bitcoins purchased at an average price of $30,200.MicroStrategy (Nasdaq: MSTR), the business-intelligence software company that’s taken to accumulating bitcoin, said it bought approximately 660 bitcoins for around $25 million between Dec. 30, 2021 and Jan. 31, 2022.The company paid an average price of $37,865 per bitcoin, it said in a statement.Tysons Corner, Virginia-based MicroStrategy now holds a total of 125,051 bitcoins, valued at about $4.8 billion at the current bitcoin price of $38,700.Shares of MicroStrategy have fallen around 34% over the last month.CEO Michael Saylor has been insistent that the company has no plans to sell its bitcoin holdings and is in for the long-term.","news_type":1,"symbols_score_info":{"MSTR":0.9}},"isVote":1,"tweetType":1,"viewCount":1653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091978587,"gmtCreate":1643768729351,"gmtModify":1676533853898,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Above ok!","listText":"Above ok!","text":"Above ok!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091978587","repostId":"2208633473","repostType":4,"isVote":1,"tweetType":1,"viewCount":2144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091973784,"gmtCreate":1643768538374,"gmtModify":1676533853851,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091973784","repostId":"2208359771","repostType":4,"isVote":1,"tweetType":1,"viewCount":653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9091972266,"gmtCreate":1643768850684,"gmtModify":1676533853939,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091972266","repostId":"1100073306","repostType":4,"repost":{"id":"1100073306","kind":"news","pubTimestamp":1643762185,"share":"https://ttm.financial/m/news/1100073306?lang=en_US&edition=fundamental","pubTime":"2022-02-02 08:36","market":"us","language":"en","title":"AT&T Is Getting Closer to a Clean Slate. Here’s What Comes Next","url":"https://stock-news.laohu8.com/highlight/detail?id=1100073306","media":"Barron's","summary":"After a saga of misguided M&A, there’s still work to be done for AT&T. Patrick T. Fallon/AFP via Get","content":"<html><head></head><body><p>After a saga of misguided M&amp;A, there’s still work to be done for AT&amp;T. Patrick T. Fallon/AFP via Getty Images</p><p>AT&amp;T shed some light on its pending exit from the media business on Tuesday, elaborating on the mechanics of this year’s mega-transaction to spin off WarnerMedia and merge it with Discovery. It’s one more step toward putting a saga of misguided M&amp;A behind it, but there’s still work to be done.</p><p>AT&amp;T (ticker: T) spent much of the past decade bulking up and dishing out billions of dollars on several acquisitions. The biggest were a $66 billion deal for DirecTV, which closed in July 2015, and the $106 billion acquisition of Time Warner, which closed in June 2018. That brought the 145-year-old phone business into new and more cyclical industries, and at one point made it the most-indebted company in the U.S.</p><p>Since the start of 2021 and under a new CEO, John Stankey, AT&amp;T has been slimming down. A spinoff of DirecTV and the company’s other pay-TV operations was announced and completed last year. Its Xandr advertising platform is being sold to Microsoft ( MSFT ). And the spinoff of WarnerMedia should close in the second quarter of this year, per management.</p><p>It will leave AT&amp;T with a telecom-only portfolio of businesses focused on 5G wireless and fiber-optic broadband. Those are high fixed-cost businesses, but also bring attractive economies of scale and recurring revenue from subscribers.</p><p>Shedding its conglomerate structure won’t make the challenges AT&amp;T faces in its telecom businesses go away, but it will allow management to focus time and resources on solving them. Competitive dynamics in both wired and wireless communications appear to be getting more intense, especially as industry subscriber growth slows following a pandemic-era boost. And AT&amp;T requires tens of billions of dollars in capital expenditures to improve its 5G and fiber networks.</p><p>AT&amp;T plans to expand its 5G C-band network to 200 million people in the U.S. by the end of 2023, and wants to reach 30 million homes and businesses with its fiber network by the end of 2025.</p><p>AT&amp;T will have more financial firepower to throw at those goals. Management expects $20 billion of annual free cash flow from the post-WarnerMedia telecom company, with 40% of that, or $8 billion, going toward its dividend. That compares with a $15 billion annual dividend commitment prior to the spinoff. The new payout will be some $1.11 per share annually, or a 6.3% yield at current prices (adjusting for the roughly $6.70 a share in Warner Bros. Discovery stock that AT&amp;T holders will receive). It matches the projections that AT&amp;T gave when announcing the transaction in May 2021.</p><p>AT&amp;T management expects to spend around $24 billion on capital investments in 2022. And the company will get an estimated $43 billion via the WarnerMedia transaction to put toward paying down debt. Management expects to get net debt to adjusted earnings before interest, taxes, depreciation, and amortization—or Ebitda—down to 2.5 times by the end of 2023. That compares with about 3.2 times today.</p><p>The result should be a leaner, meaner AT&amp;T that’s better equipped to face its challenges, but investors will want to see proof after feeling burned by years of management decisions that look poor in hindsight. Next up is a virtual investor day on March 11 focused on the post-WarnerMedia telecom business, which could include new long-term targets and plans.</p><p>The closing of the transaction itself should also bring some relief. Investors interested in Warner Bros. Discovery can shift to that stock, and those who want a yield-generating telecom stock can double down on AT&amp;T. Most of all, it will allow Wall Street to focus on AT&amp;T’s fundamentals and judge management on operations—and put an end to years of distracting and expensive M&amp;A sagas.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AT&T Is Getting Closer to a Clean Slate. Here’s What Comes Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAT&T Is Getting Closer to a Clean Slate. Here’s What Comes Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-02 08:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/att-media-spin-51643742609?mod=hp_LEAD_1><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a saga of misguided M&A, there’s still work to be done for AT&T. Patrick T. Fallon/AFP via Getty ImagesAT&T shed some light on its pending exit from the media business on Tuesday, elaborating on...</p>\n\n<a href=\"https://www.barrons.com/articles/att-media-spin-51643742609?mod=hp_LEAD_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"T":"At&T"},"source_url":"https://www.barrons.com/articles/att-media-spin-51643742609?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100073306","content_text":"After a saga of misguided M&A, there’s still work to be done for AT&T. Patrick T. Fallon/AFP via Getty ImagesAT&T shed some light on its pending exit from the media business on Tuesday, elaborating on the mechanics of this year’s mega-transaction to spin off WarnerMedia and merge it with Discovery. It’s one more step toward putting a saga of misguided M&A behind it, but there’s still work to be done.AT&T (ticker: T) spent much of the past decade bulking up and dishing out billions of dollars on several acquisitions. The biggest were a $66 billion deal for DirecTV, which closed in July 2015, and the $106 billion acquisition of Time Warner, which closed in June 2018. That brought the 145-year-old phone business into new and more cyclical industries, and at one point made it the most-indebted company in the U.S.Since the start of 2021 and under a new CEO, John Stankey, AT&T has been slimming down. A spinoff of DirecTV and the company’s other pay-TV operations was announced and completed last year. Its Xandr advertising platform is being sold to Microsoft ( MSFT ). And the spinoff of WarnerMedia should close in the second quarter of this year, per management.It will leave AT&T with a telecom-only portfolio of businesses focused on 5G wireless and fiber-optic broadband. Those are high fixed-cost businesses, but also bring attractive economies of scale and recurring revenue from subscribers.Shedding its conglomerate structure won’t make the challenges AT&T faces in its telecom businesses go away, but it will allow management to focus time and resources on solving them. Competitive dynamics in both wired and wireless communications appear to be getting more intense, especially as industry subscriber growth slows following a pandemic-era boost. And AT&T requires tens of billions of dollars in capital expenditures to improve its 5G and fiber networks.AT&T plans to expand its 5G C-band network to 200 million people in the U.S. by the end of 2023, and wants to reach 30 million homes and businesses with its fiber network by the end of 2025.AT&T will have more financial firepower to throw at those goals. Management expects $20 billion of annual free cash flow from the post-WarnerMedia telecom company, with 40% of that, or $8 billion, going toward its dividend. That compares with a $15 billion annual dividend commitment prior to the spinoff. The new payout will be some $1.11 per share annually, or a 6.3% yield at current prices (adjusting for the roughly $6.70 a share in Warner Bros. Discovery stock that AT&T holders will receive). It matches the projections that AT&T gave when announcing the transaction in May 2021.AT&T management expects to spend around $24 billion on capital investments in 2022. And the company will get an estimated $43 billion via the WarnerMedia transaction to put toward paying down debt. Management expects to get net debt to adjusted earnings before interest, taxes, depreciation, and amortization—or Ebitda—down to 2.5 times by the end of 2023. That compares with about 3.2 times today.The result should be a leaner, meaner AT&T that’s better equipped to face its challenges, but investors will want to see proof after feeling burned by years of management decisions that look poor in hindsight. Next up is a virtual investor day on March 11 focused on the post-WarnerMedia telecom business, which could include new long-term targets and plans.The closing of the transaction itself should also bring some relief. Investors interested in Warner Bros. Discovery can shift to that stock, and those who want a yield-generating telecom stock can double down on AT&T. Most of all, it will allow Wall Street to focus on AT&T’s fundamentals and judge management on operations—and put an end to years of distracting and expensive M&A sagas.","news_type":1,"symbols_score_info":{"T":0.9}},"isVote":1,"tweetType":1,"viewCount":2524,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091661999,"gmtCreate":1643853421813,"gmtModify":1676533863822,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091661999","repostId":"1178657302","repostType":4,"repost":{"id":"1178657302","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1643804908,"share":"https://ttm.financial/m/news/1178657302?lang=en_US&edition=fundamental","pubTime":"2022-02-02 20:28","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1178657302","media":"Benzinga","summary":"Keybanc lifted the price target for Alphabet Inc. from $3,090 to $3,400. Alphabet shares surged 11% ","content":"<html><head></head><body><ul><li>Keybanc lifted the price target for <b>Alphabet Inc.</b> from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading.</li><li>Wedbush cut the price target on <b>Starbucks Corporation</b> from $110 to $106. Starbucks shares fell 2.5% to $96.29 in pre-market trading.</li><li>Cowen &amp; Co. cut <b>Clover Health Investments, Corp.</b> price target from $7 to $3. Clover Health Investments shares rose 6.5% to $2.97 in pre-market trading.</li><li>UBS lowered <b>Zimmer Biomet Holdings, Inc.</b> price target from $172 to $130. Zimmer Biomet shares fell 0.2% to $123.80 in pre-market trading.</li><li>Citigroup cut <b>loanDepot, Inc.</b> price target from $12 to $5. loanDepot shares fell 4.9% to close at $4.46 on Tuesday.</li></ul><ul><li>Raymond James boosted the price target for <b>NXP Semiconductors N.V.</b> from $250 to $260. NXP Semiconductors shares rose 1.4% to $211.10 in pre-market trading.</li><li>SVB Leerink raised the price target on <b>Bio-Techne Corporation</b> from $530 to $575. Bio-Techne shares rose 0.1% to $401.76 in pre-market trading.</li><li>Goldman Sachs lowered <b>2U, Inc.</b> price target from $42 to $25. 2U shares rose 6.7% to $17.79 in pre-market trading.</li><li>UBS cut the price target on <b>Etsy, Inc.</b> from $215 to $180. Etsy shares rose 2% to $155.16 in pre-market trading.</li><li>Keybanc cut <b>PayPal Holdings, Inc.</b> price target from $250 to $200. PayPal shares fell 16% to $148.00 in pre-market trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-02-02 20:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><ul><li>Keybanc lifted the price target for <b>Alphabet Inc.</b> from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading.</li><li>Wedbush cut the price target on <b>Starbucks Corporation</b> from $110 to $106. Starbucks shares fell 2.5% to $96.29 in pre-market trading.</li><li>Cowen &amp; Co. cut <b>Clover Health Investments, Corp.</b> price target from $7 to $3. Clover Health Investments shares rose 6.5% to $2.97 in pre-market trading.</li><li>UBS lowered <b>Zimmer Biomet Holdings, Inc.</b> price target from $172 to $130. Zimmer Biomet shares fell 0.2% to $123.80 in pre-market trading.</li><li>Citigroup cut <b>loanDepot, Inc.</b> price target from $12 to $5. loanDepot shares fell 4.9% to close at $4.46 on Tuesday.</li></ul><ul><li>Raymond James boosted the price target for <b>NXP Semiconductors N.V.</b> from $250 to $260. NXP Semiconductors shares rose 1.4% to $211.10 in pre-market trading.</li><li>SVB Leerink raised the price target on <b>Bio-Techne Corporation</b> from $530 to $575. Bio-Techne shares rose 0.1% to $401.76 in pre-market trading.</li><li>Goldman Sachs lowered <b>2U, Inc.</b> price target from $42 to $25. 2U shares rose 6.7% to $17.79 in pre-market trading.</li><li>UBS cut the price target on <b>Etsy, Inc.</b> from $215 to $180. Etsy shares rose 2% to $155.16 in pre-market trading.</li><li>Keybanc cut <b>PayPal Holdings, Inc.</b> price target from $250 to $200. PayPal shares fell 16% to $148.00 in pre-market trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp","GOOGL":"谷歌A","ZBH":"齐默巴奥米特控股","PYPL":"PayPal","TECH":"Techne Corporation","ETSY":"Etsy, Inc.","SBUX":"星巴克","NXPI":"恩智浦","TWOU":"2U Inc","LDI":"loanDepot, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178657302","content_text":"Keybanc lifted the price target for Alphabet Inc. from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading.Wedbush cut the price target on Starbucks Corporation from $110 to $106. Starbucks shares fell 2.5% to $96.29 in pre-market trading.Cowen & Co. cut Clover Health Investments, Corp. price target from $7 to $3. Clover Health Investments shares rose 6.5% to $2.97 in pre-market trading.UBS lowered Zimmer Biomet Holdings, Inc. price target from $172 to $130. Zimmer Biomet shares fell 0.2% to $123.80 in pre-market trading.Citigroup cut loanDepot, Inc. price target from $12 to $5. loanDepot shares fell 4.9% to close at $4.46 on Tuesday.Raymond James boosted the price target for NXP Semiconductors N.V. from $250 to $260. NXP Semiconductors shares rose 1.4% to $211.10 in pre-market trading.SVB Leerink raised the price target on Bio-Techne Corporation from $530 to $575. Bio-Techne shares rose 0.1% to $401.76 in pre-market trading.Goldman Sachs lowered 2U, Inc. price target from $42 to $25. 2U shares rose 6.7% to $17.79 in pre-market trading.UBS cut the price target on Etsy, Inc. from $215 to $180. Etsy shares rose 2% to $155.16 in pre-market trading.Keybanc cut PayPal Holdings, Inc. price target from $250 to $200. PayPal shares fell 16% to $148.00 in pre-market trading.","news_type":1,"symbols_score_info":{"CLOV":0.9,"TECH":0.9,"TWOU":0.9,"SBUX":0.9,"ZBH":0.9,"LDI":0.9,"PYPL":0.9,"GOOGL":0.9,"NXPI":0.9,"ETSY":0.9}},"isVote":1,"tweetType":1,"viewCount":1798,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091660170,"gmtCreate":1643852941827,"gmtModify":1676533863751,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091660170","repostId":"1196109622","repostType":4,"repost":{"id":"1196109622","kind":"news","pubTimestamp":1643852105,"share":"https://ttm.financial/m/news/1196109622?lang=en_US&edition=fundamental","pubTime":"2022-02-03 09:35","market":"us","language":"en","title":"2 Biotech Stocks That Could Make You Richer","url":"https://stock-news.laohu8.com/highlight/detail?id=1196109622","media":"Motley Fool","summary":"Investing in the stock market won't make you rich overnight. But with a patient approach to investin","content":"<html><head></head><body><p>Investing in the stock market won&#39;t make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.</p><p>Let&#39;s address the second part of this strategy: picking the right stocks, which isn&#39;t always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a> and <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a>. Here&#39;s why.</p><p>1. <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a></p><p>To say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.</p><p>On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.</p><p>However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called<b>2Seventy Bio</b>.</p><p>Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.</p><p>There are few treatments for TDT. But Bluebird&#39;s version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.</p><p>The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).</p><p>ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.</p><p>Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.</p><p>However, Bluebird&#39;s current market cap is barely over $500 million. The market isn&#39;t putting much value in the company&#39;s programs at all. That&#39;s what makes this biotech a potentially attractive option. If the company&#39;s master plan actualizes, its shares could skyrocket.</p><p>2. <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a></p><p>Exelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company&#39;s sales. But thebiotech&#39;s reliance on its crown jewel doesn&#39;t bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.</p><p>Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.</p><p>First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it&#39;s estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it&#39;s predicting $1.3 billion to $1.4 billion in revenue.</p><p>Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That&#39;s good news for Exelixis and its shareholders.</p><p>The biotech is now looking to replicate the success it&#39;s had with Cabometyx. It&#39;s advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.</p><p>Within the next couple of years, these products should be moving into late-stage studies. Exelixis&#39; forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotech Stocks That Could Make You Richer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotech Stocks That Could Make You Richer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯"},"source_url":"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196109622","content_text":"Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: Bluebird Bio and Exelixis. Here's why.1. Bluebird BioTo say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called2Seventy Bio.Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.2. ExelixisExelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.","news_type":1,"symbols_score_info":{"EXEL":0.9,"BLUE":0.9}},"isVote":1,"tweetType":1,"viewCount":2007,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091972866,"gmtCreate":1643768833295,"gmtModify":1676533853931,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091972866","repostId":"2208351417","repostType":4,"isVote":1,"tweetType":1,"viewCount":2098,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091976377,"gmtCreate":1643768778805,"gmtModify":1676533853907,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Gd info","listText":"Gd info","text":"Gd info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091976377","repostId":"1181481003","repostType":4,"repost":{"id":"1181481003","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643722728,"share":"https://ttm.financial/m/news/1181481003?lang=en_US&edition=fundamental","pubTime":"2022-02-01 21:38","market":"us","language":"en","title":"MicroStrategy shares rose 7% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1181481003","media":"Tiger Newspress","summary":"MicroStrategy shares rose 7% in premarket trading.As of Jan. 31, the company held about 125,051 bitc","content":"<html><head></head><body><p>MicroStrategy shares rose 7% in premarket trading.<img src=\"https://static.tigerbbs.com/9682bd3ba54feb42c63bc9be06e419fa\" tg-width=\"699\" tg-height=\"598\" width=\"100%\" height=\"auto\"/></p><p>As of Jan. 31, the company held about 125,051 bitcoins purchased at an average price of $30,200.</p><p>MicroStrategy (Nasdaq: MSTR), the business-intelligence software company that’s taken to accumulating bitcoin, said it bought approximately 660 bitcoins for around $25 million between Dec. 30, 2021 and Jan. 31, 2022.</p><p>The company paid an average price of $37,865 per bitcoin, it said in a statement.</p><p>Tysons Corner, Virginia-based MicroStrategy now holds a total of 125,051 bitcoins, valued at about $4.8 billion at the current bitcoin price of $38,700.</p><p>Shares of MicroStrategy have fallen around 34% over the last month.</p><p>CEO Michael Saylor has been insistent that the company has no plans to sell its bitcoin holdings and is in for the long-term.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MicroStrategy shares rose 7% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicroStrategy shares rose 7% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-01 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>MicroStrategy shares rose 7% in premarket trading.<img src=\"https://static.tigerbbs.com/9682bd3ba54feb42c63bc9be06e419fa\" tg-width=\"699\" tg-height=\"598\" width=\"100%\" height=\"auto\"/></p><p>As of Jan. 31, the company held about 125,051 bitcoins purchased at an average price of $30,200.</p><p>MicroStrategy (Nasdaq: MSTR), the business-intelligence software company that’s taken to accumulating bitcoin, said it bought approximately 660 bitcoins for around $25 million between Dec. 30, 2021 and Jan. 31, 2022.</p><p>The company paid an average price of $37,865 per bitcoin, it said in a statement.</p><p>Tysons Corner, Virginia-based MicroStrategy now holds a total of 125,051 bitcoins, valued at about $4.8 billion at the current bitcoin price of $38,700.</p><p>Shares of MicroStrategy have fallen around 34% over the last month.</p><p>CEO Michael Saylor has been insistent that the company has no plans to sell its bitcoin holdings and is in for the long-term.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSTR":"Strategy"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181481003","content_text":"MicroStrategy shares rose 7% in premarket trading.As of Jan. 31, the company held about 125,051 bitcoins purchased at an average price of $30,200.MicroStrategy (Nasdaq: MSTR), the business-intelligence software company that’s taken to accumulating bitcoin, said it bought approximately 660 bitcoins for around $25 million between Dec. 30, 2021 and Jan. 31, 2022.The company paid an average price of $37,865 per bitcoin, it said in a statement.Tysons Corner, Virginia-based MicroStrategy now holds a total of 125,051 bitcoins, valued at about $4.8 billion at the current bitcoin price of $38,700.Shares of MicroStrategy have fallen around 34% over the last month.CEO Michael Saylor has been insistent that the company has no plans to sell its bitcoin holdings and is in for the long-term.","news_type":1,"symbols_score_info":{"MSTR":0.9}},"isVote":1,"tweetType":1,"viewCount":1653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9092993723,"gmtCreate":1644504373762,"gmtModify":1676533934446,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"sigh","listText":"sigh","text":"sigh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092993723","repostId":"696619638","repostType":1,"repost":{"id":696619638,"gmtCreate":1640679651873,"gmtModify":1676532477490,"author":{"id":"9000000000000695","authorId":"9000000000000695","name":"BaronLyly","avatar":"https://static.tigerbbs.com/2002537f0b7be973a9a9a72fea618459","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000695","idStr":"9000000000000695"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MARA\">$Marathon Digital Holdings Inc(MARA)$</a> you won’t see much growth here . You should be banking on FRTTF<a href=\"https://laohu8.com/S/FRTTF\">$FORTRESS TECHNOLOGIES INC.(FRTTF)$</a> and LUXXF<a href=\"https://laohu8.com/S/LUXFF\">$LUXXFOLIO HLDGS INC(LUXFF)$</a> as they will double , triple and very cheap . I bought MARA and RIOT<a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$</a> as a penny stock last year so jump on same. Easier to double and triple your money if you buy low hanging fruit .looks like accumulation before the next leg up","listText":"<a href=\"https://laohu8.com/S/MARA\">$Marathon Digital Holdings Inc(MARA)$</a> you won’t see much growth here . You should be banking on FRTTF<a href=\"https://laohu8.com/S/FRTTF\">$FORTRESS TECHNOLOGIES INC.(FRTTF)$</a> and LUXXF<a href=\"https://laohu8.com/S/LUXFF\">$LUXXFOLIO HLDGS INC(LUXFF)$</a> as they will double , triple and very cheap . I bought MARA and RIOT<a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$</a> as a penny stock last year so jump on same. Easier to double and triple your money if you buy low hanging fruit .looks like accumulation before the next leg up","text":"$Marathon Digital Holdings Inc(MARA)$ you won’t see much growth here . You should be banking on FRTTF$FORTRESS TECHNOLOGIES INC.(FRTTF)$ and LUXXF$LUXXFOLIO HLDGS INC(LUXFF)$ as they will double , triple and very cheap . I bought MARA and RIOT$Riot Blockchain, Inc.(RIOT)$ as a penny stock last year so jump on same. Easier to double and triple your money if you buy low hanging fruit .looks like accumulation before the next leg up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/696619638","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098309708,"gmtCreate":1644020507382,"gmtModify":1676533881869,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098309708","repostId":"2209345239","repostType":4,"repost":{"id":"2209345239","kind":"news","pubTimestamp":1644016922,"share":"https://ttm.financial/m/news/2209345239?lang=en_US&edition=fundamental","pubTime":"2022-02-05 07:22","market":"us","language":"en","title":"Apple Aims to Debut a New Low-Cost 5G iPhone and iPad in Early March","url":"https://stock-news.laohu8.com/highlight/detail?id=2209345239","media":"Bloomberg","summary":"Apple Inc. is targeting a date on or near March 8 to unveil a new low-cost iPhone and an updated iPad, according to people with knowledge of the matter, kicking off a potentially record-setting year f","content":"<div>\n<p>Apple Inc. is targeting a date on or near March 8 to unveil a new low-cost iPhone and an updated iPad, according to people with knowledge of the matter, kicking off a potentially record-setting year ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apple-aims-debut-low-cost-193822024.html\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Aims to Debut a New Low-Cost 5G iPhone and iPad in Early March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Aims to Debut a New Low-Cost 5G iPhone and iPad in Early March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/apple-aims-debut-low-cost-193822024.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple Inc. is targeting a date on or near March 8 to unveil a new low-cost iPhone and an updated iPad, according to people with knowledge of the matter, kicking off a potentially record-setting year ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apple-aims-debut-low-cost-193822024.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4017":"黄金","BK4534":"瑞士信贷持仓","BK4515":"5G概念","BK4559":"巴菲特持仓","AAPL":"苹果","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4527":"明星科技股","BK4554":"元宇宙及AR概念","BK4501":"段永平概念","BK4507":"流媒体概念","BK4566":"资本集团","BK4553":"喜马拉雅资本持仓","NGD":"New Gold","BK4550":"红杉资本持仓","BK4505":"高瓴资本持仓","BK4170":"电脑硬件、储存设备及电脑周边"},"source_url":"https://finance.yahoo.com/news/apple-aims-debut-low-cost-193822024.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2209345239","content_text":"Apple Inc. is targeting a date on or near March 8 to unveil a new low-cost iPhone and an updated iPad, according to people with knowledge of the matter, kicking off a potentially record-setting year for product launches.The announcement will mark Apple’s first major event since a new MacBook Pro debuted in October. Like the company’s other recent launches, it’s expected to be an online presentation rather than in-person, said the people, who asked not to be identified because the deliberations are private.Apple is coming off a holiday quarter that far exceeded Wall Street predictions, helping quell fears that supply-chain problems would hurt sales. Now the company is setting its sights higher for 2022. The March announcements -- along with the usual flood of product news expected later in 2022 -- suggest Apple will introduce its biggest crop of new devices ever in a single year.Given that the planned timing is still more than a month away, the company’s plans may change in the face of production delays or other changes, the people said. An Apple spokeswoman declined to comment on the company’s plans.The new phone will be the first update to the iPhone SE model in two years, adding 5G network capabilities, an improved camera and a faster processor. But the design itself is expected to be similar to the current version, which debuted in April 2020.The new iPad, meanwhile, will be an update to the Air model that features a faster processor and 5G. The company is also planning a new Mac with Apple-designed chips, which could also come as early as March.In addition to announcing new devices, the company is planning to release iOS 15.4 in the first half of March, the people said. The software update will add Face ID support for people wearing masks to iPhones and iPads, making it easier for users to unlock their devices. It also has new emojis and Universal Control, which lets customers use a single keyboard and trackpad across multiple iPads and Macs.Following the March event, the company will likely hold its annual Worldwide Developers Conference in June to announce software updates for the iPhone, iPad, Mac and Apple Watch. It’s then expected to hold multiple keynote events in the fall to launch the iPhone 14 and new Macs.The 2022 lineup is likely to include new iMac and Mac Pro desktops, a redesigned MacBook Air, an updated low-end MacBook Pro, three Apple Watches, four iPhone 14 models and new AirPods. The company is also planning new services, such as a feature that lets the iPhone accept payments with the tap of a credit card.Apple is working on a high-end mixed reality headset as well, but that’s now more likely to be released in 2023. The company had aimed to announce the device as early as the end of 2022, but development challenges have delayed the timing, Bloomberg reported last month.","news_type":1,"symbols_score_info":{"NGD":1,"AAPL":1}},"isVote":1,"tweetType":1,"viewCount":2334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9095302361,"gmtCreate":1644813840775,"gmtModify":1676533964421,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095302361","repostId":"9092755406","repostType":1,"repost":{"id":9092755406,"gmtCreate":1644742715482,"gmtModify":1676533958368,"author":{"id":"3527667591235607","authorId":"3527667591235607","name":"OptionPlus","avatar":"https://static.tigerbbs.com/e8009c23927adcf8b5e1e1d101178392","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667591235607","idStr":"3527667591235607"},"themes":[],"title":"Option Recap: Don't take chestnuts out of the fire","htmlText":"The general idea is similar to last week, so I dont do detailed review，you can read&nbsp;my&nbsp;review&nbsp;for&nbsp;last&nbsp;week&nbsp;if&nbsp;you&nbsp;like. The&nbsp;S&amp;P&nbsp;500&nbsp;fell&nbsp;be&nbsp;its&nbsp;anual&nbsp;support&nbsp;line&nbsp;again&nbsp;in&nbsp;the&nbsp;second&nbsp;half&nbsp;of&nbsp;Friday&nbsp;night&nbsp;with&nbsp;geopolitical shocks.&nbsp;And&nbsp;It&nbsp;closed&nbsp;at&nbsp;a&nbsp;weely&nbsp;low&nbsp;point.&nbsp;My&nbsp;feeling&nbsp;is&nbsp;similar&nbsp;to&nbsp;last&nbsp;week,&nbsp;it&nbsp;might&nbsp;draw&nbsp;a&nbsp;right-leg. There&nbsp;is&nbsp;a&nbsp;small&nbsp;double-top&nbsp;in&nbsp;past&nbsp;two&nbsp;weeks,&nbsp;and&nbsp;both&nbsp;small&nbsp;tops&nbsp;did&nbsp;not&nbsp;rally&nbsp;to&nbsp;the&nbsp;MA50,&nbsp;it&nbsp;was&nbsp;not&nbsp;strong.&nbsp;As&nbsp;","listText":"The general idea is similar to last week, so I dont do detailed review，you can read&nbsp;my&nbsp;review&nbsp;for&nbsp;last&nbsp;week&nbsp;if&nbsp;you&nbsp;like. The&nbsp;S&amp;P&nbsp;500&nbsp;fell&nbsp;be&nbsp;its&nbsp;anual&nbsp;support&nbsp;line&nbsp;again&nbsp;in&nbsp;the&nbsp;second&nbsp;half&nbsp;of&nbsp;Friday&nbsp;night&nbsp;with&nbsp;geopolitical shocks.&nbsp;And&nbsp;It&nbsp;closed&nbsp;at&nbsp;a&nbsp;weely&nbsp;low&nbsp;point.&nbsp;My&nbsp;feeling&nbsp;is&nbsp;similar&nbsp;to&nbsp;last&nbsp;week,&nbsp;it&nbsp;might&nbsp;draw&nbsp;a&nbsp;right-leg. There&nbsp;is&nbsp;a&nbsp;small&nbsp;double-top&nbsp;in&nbsp;past&nbsp;two&nbsp;weeks,&nbsp;and&nbsp;both&nbsp;small&nbsp;tops&nbsp;did&nbsp;not&nbsp;rally&nbsp;to&nbsp;the&nbsp;MA50,&nbsp;it&nbsp;was&nbsp;not&nbsp;strong.&nbsp;As&nbsp;","text":"The general idea is similar to last week, so I dont do detailed review，you can read my review for last week if you like. The S&P 500 fell be its anual support line again in the second half of Friday night with geopolitical shocks. And It closed at a weely low point. My feeling is similar to last week, it might draw a right-leg. There is a small double-top in past two weeks, and both small tops did not rally to the MA50, it was not strong. As","images":[{"img":"https://static.tigerbbs.com/ed0379ee21b4ee0665a09e0210e754a4","width":"2096","height":"1220"},{"img":"https://static.tigerbbs.com/cbe5974fdf018ff5b17c62544ec1de99","width":"2144","height":"1534"},{"img":"https://static.tigerbbs.com/cc0af868946c5e3165b2c5dad80913e6","width":"2198","height":"1332"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092755406","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098309592,"gmtCreate":1644020478679,"gmtModify":1676533881861,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098309592","repostId":"1133568920","repostType":4,"repost":{"id":"1133568920","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643879102,"share":"https://ttm.financial/m/news/1133568920?lang=en_US&edition=fundamental","pubTime":"2022-02-03 17:05","market":"us","language":"en","title":"Metauniverse Stocks Slid in Premarket Trading,With Block and Roblox Falling Over 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133568920","media":"Tiger Newspress","summary":"Metauniverse stocks slid in premarket trading, with Block and Roblox falling over6%.In Meta’s financ","content":"<html><head></head><body><p>Metauniverse stocks slid in premarket trading, with Block and Roblox falling over6%.</p><p><img src=\"https://static.tigerbbs.com/9bf35520675a25a430afdadb73298193\" tg-width=\"287\" tg-height=\"191\" referrerpolicy=\"no-referrer\"/></p><p>In Meta’s financial result ,it disclosed the data of FRL department including metauniverse strategy for the first time. The company expected that the investment in metauniverse will reduce the operating profit by about US $10 billion in 2021, and FRL will not make a profit in the short term.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Metauniverse Stocks Slid in Premarket Trading,With Block and Roblox Falling Over 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetauniverse Stocks Slid in Premarket Trading,With Block and Roblox Falling Over 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-03 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Metauniverse stocks slid in premarket trading, with Block and Roblox falling over6%.</p><p><img src=\"https://static.tigerbbs.com/9bf35520675a25a430afdadb73298193\" tg-width=\"287\" tg-height=\"191\" referrerpolicy=\"no-referrer\"/></p><p>In Meta’s financial result ,it disclosed the data of FRL department including metauniverse strategy for the first time. The company expected that the investment in metauniverse will reduce the operating profit by about US $10 billion in 2021, and FRL will not make a profit in the short term.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133568920","content_text":"Metauniverse stocks slid in premarket trading, with Block and Roblox falling over6%.In Meta’s financial result ,it disclosed the data of FRL department including metauniverse strategy for the first time. The company expected that the investment in metauniverse will reduce the operating profit by about US $10 billion in 2021, and FRL will not make a profit in the short term.","news_type":1,"symbols_score_info":{"SQ":0.9,"RBLX":0.9}},"isVote":1,"tweetType":1,"viewCount":2250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091978587,"gmtCreate":1643768729351,"gmtModify":1676533853898,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Above ok!","listText":"Above ok!","text":"Above ok!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091978587","repostId":"2208633473","repostType":4,"isVote":1,"tweetType":1,"viewCount":2144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091973784,"gmtCreate":1643768538374,"gmtModify":1676533853851,"author":{"id":"3582933493509774","authorId":"3582933493509774","name":"linghui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582933493509774","idStr":"3582933493509774"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091973784","repostId":"2208359771","repostType":4,"isVote":1,"tweetType":1,"viewCount":653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}